Bilici, AhmetUysal, MukreminMenekse, SerkanAkin, SemihYildiz, FatihTuran, MerveTurhal, Serdar2025-05-102025-05-1020220735-79071532-419210.1080/07357907.2021.20179522-s2.0-85121803055https://doi.org/10.1080/07357907.2021.2017952https://hdl.handle.net/20.500.14720/8257Turan, Merve/0000-0003-4021-6095; Tanriverdi, Ozgur/0000-0002-0598-7284; Turker, Sema/0000-0001-9040-7266; Uslu, Ruchan/0000-0002-9584-6134; Erdem, Dilek/0000-0001-6495-6712; Beypinar, Ismail/0000-0002-0853-4096Purpose This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings. Methods Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER - MBC patients.eninfo:eu-repo/semantics/closedAccessEverolimusExemestaneMetastatic Breast CancerHormone Receptor-PositiveHer - NegativeEfficacyArticle402Q4Q319920934894960WOS:000734258300001